Changes of HMGB1 and sRAGE during the recovery of COPD exacerbation

Abstract

Background

Acute exacerbation of chronic obstructive pulmonary disease is associated with increased airway and systemic inflammation. However, the correlation between acute exacerbation/convalescence of chronic obstructive pulmonary disease (COPD) and simultaneous changes of high mobility group protein B1 (HMGB1) and soluble RAGE (sRAGE) levels has not been clearly clarified. The aim of this study was to assess these issues.

Methods

A total of 44 COPD patients were recruited. Following a structured interview, plasma levels of HMGB1, sRAGE, fibrinogen and serum level of high-sensitivity C-reactive protein (hsCRP) were measured in patients with acute exacerbation of COPD (AECOPD) within 24 h of hospitalization and pre-discharge (convalescence). All patients were examined with spirometry in convalescence of COPD.

Results

There was a significant decline in plasma HMGB1 (P<0.01), sRAGE (P<0.05), fibrinogen (P<0.01) and serum hsCRP (P<0.01) levels from acute exacerbation to convalescence phase of COPD. Changes of sRAGE was significantly correlated with changes of HMGB1 (r=0.4, P=0.007). COPD disease status correlated with the ratio of HMGB1/sRAGE, but not gender, age, course of disease, smoking history and FEV1% pred. Levels of HMGB1 and sRAGE were the highest in the current smoker group, and significantly decreased in ex-smoker group in both acute exacerbation and convalescence phase of COPD, however, their levels in never smoker group were higher than ex-smoker group in either phase of COPD.

Conclusions

HMGB1 and sRAGE levels were dynamically changed between exacerbation and convalescence phase of COPD, HMGB1 and sRAGE were likely not only a potential marker in COPD exacerbation but also a therapeutic target for COPD treatment.

Introduction

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, which is characterized by irreversible airflow limitation, and usually progressive and associated with abnormal inflammatory responses of the lung to noxious particles or gases (1). Despite the involvement of airway inflammation in the development of COPD, current anti-inflammatory therapies poorly prevent the deterioration of COPD, which indicate that more efforts are need to explore novel molecular mechanisms and targets involved in the disease pathogenesis and progression (2).

High mobility group protein B1 (HMGB1) is an abundant chromatin protein that acts as a cytokine when released into the extracellular milieu by necrotic and inflammatory cells. It is regarded as a marker of tissue injury and a mediator of inflammation. It has been reported that extracellular HMGB1 contributes to the pathogenesis of many inflammatory diseases, such as sepsis, acute lung injury, adult respiratory distress syndrome, cystic fibrosis and systemic lupus erythematosus (3). HMGB1 has been shown to transduce cellular signals by interacting with at least three receptors: the receptor for advanced glycation end-products (RAGE), toll-like receptors (TLR) 2/4. RAGE is the first identified receptor of HMGB1, binding of HMGB1 to cell surface RAGE results in generation of reactive oxygen species (ROS) and activation of the transcription factor NF-κB, which further promotes cytokines production, all these bioactivators stimulates immune and inflammatory responses (4).

RAGE belongs to the immunoglobulin superfamily of cell surface molecules. RAGE is expressed as both a transmembrane molecule and a soluble molecule. The soluble form seems to be produced by either alternative mRNA splicing or proteolytic cleavage of transmermbrane RAGE (mRAGE). Soluble RAGE (sRAGE) is capable of binding the same RAGE ligands, including HMGB1, it has been proposed that sRAGE acts as a decoy receptor, preventing the interaction of mRAGE with its ligands (5). In the majority of healthy mature tissues, RAGE is expressed at a low basal level, its expression is up-regulated at sites of various pathologies, such as diabetes, atherosclerosis and Alzheimer’s disease (5). Pulmonary tissues express relatively high basal levels of RAGE, especially in alveolar epithelial cells (6), suggesting that HMGB1/RAGE pathway may have a number of functions in the lung. Since sRAGE presumably inhibits the activity of HMGB1, it might have potential value in the clinic to treat some lung inflammatory diseases with high level of HMGB1.

Recent studies have reported an enhanced level of HMGB1 in BAL fluid (7), sputum and circulation in patients with COPD (8). Study has shown that the level of plasma sRAGE decreases in patients with COPD in comparison with healthy controls, and its level is even lower in acute exacerbation of COPD (AECOPD) (9), however, the data are less robust. There are fewer studies simultaneously investigating changes of HMGB1, sRAGE and the ratio of HMGB1/sRAGE in acute exacerbation and convalescence phase of COPD, and determining the correlation of the levels of HMGB1, sRAGE and ratio of HMGB1/sRAGE with clinical characteristics of COPD. This study aims to clarify these issues.

Methods

Subjects

The present prospective cohort study was approved by the Research Committee of Human Investigation of Medical College of Xi’an Jiaotong University. All participants were given informed consent. Patients’ main hospitalization diagnosis, medical history, and smoking history were collected by physicians. A total of 102 patients with AECOPD were admitted to the Department of Respiratory Medicine of the Second Affiliated Hospital of Medical College, Xi’an Jiaotong University (Xi’an, Shanxi, China) between October 2012 and March 2013. Fifty-eight COPD patients with coronary artery disease, diabetes, autoimmune disease and any other conditions which could affect HMGB1and sRAGE levels were excluded. Forty-four COPD patients were recruited into this study.

Clinical variables

Detailed clinical and demographic data were obtained at the time of hospital admission. Smoking history, hospitalization time, course of disease and exacerbation frequency in previous 3 years were also collected. Laboratory measurements including total leukocyte counts, neutrophils %, serum high-sensitivity C-reactive protein (hsCRP), plasma fibrinogen; arterial blood gas analyses and chest CT were performed.

Criteria for acute exacerbation and convalescence of COPD

AECOPD is defined as the worsening of respiratory symptoms, and is diagnosed based on the presence of an increase in any two major symptoms (dyspnoea, sputum purulence and sputum quantity), or an increase in one major and one minor symptom (wheeze, sore throat, cough and nasal congestion/discharge) for at least two consecutive days according to previously accepted criteria (10). Convalescence of COPD is diagnosed on clinical grounds with the following criteria: symptoms of patient with COPD return to the pre-exacerbation level variability, physician carefully assesses the patient and confirms that the individual is medically stable enough to leave the hospital, but patients are not unstable and prone to acute exacerbation again (11).

Therapy during hospitalization

The routine treatment for AECOPD during hospitalization was as follows: all patients diagnosed with AECOPD were supplemented with low flow oxygen, intravenous infusions of methylprednisolone 0.7-1.4 mg/kg per day for the first 3 to 5 days, and switching to nebulized budesonide (2 mg, 8 hourly) for the following 6 to 9 days. Antibiotics administration was adjusted based on the results of blood tests for inflammatory markers, sputum test, and signs of pneumonia. Intravenous infusions of aminophylline and expectorants were prescribed until patients with AECOPD condition were stable. Inhaled long-acting β2 agonists were prescribed for maintenance therapy upon discharge.

Pulmonary function tests

Spirometry was performed on each subject. Reversibility assessment was conducted in COPD patients by making them inhale a short-acting β₂ agonist equivalent to 200 μg salbutamol. For hospitalized patients with acute exacerbations, spirometry was performed 12 to 17 days after the onset of exacerbation when the patients were stable enough to perform the spirometer maneuver.

Blood sample preparation

Blood was collected at the following two time points: within 24 hours of hospitalization; before discharge from hospital after treatment for 12-17 days in hospital. Blood was drawn and stored by the same researcher in the same department. Blood samples were collected aseptically in ethylenediamine tetraceticacid (EDTA)-anticoagulated tubes and stored at 4 °C. Samples were centrifuged at 1,000 g at 4 °C for 15 min, and plasma was separated and stored at –80 °C in aliquots of 1 mL until the measurements were taken.

Measurements of HMGB1, sRAGE, hsCRP and fibrinogen

Plasma HMGB1 and sRAGE levels were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits (KYM, Beijing, China). The detection limit of the kits is 0.1 ng/mL for HMGB1 and sRAGE. Each sample was run in duplicate and compared with a standard curve. The mean concentration was determined for each sample. Fibrinogen and hsCRP were measured immediately in clinic laboratory once blood plasma was acquired.

Statistical analyses

The Statistical Package for Social Sciences (SPSS), version 13.0, was used to analyze the data. Normality of distribution was examined with Kolmogorove-Smirnov test. Normally distributed data were expressed as mean ± standard deviation (SD). Non-normally distributed data were expressed as median (range). Normally distributed data were compared using paired t-tests between acute exacerbation and convalescence phase of COPD; non-normally distributed data were analyzed using wilcoxon signed Ranks test. Frequency data were compared with χ² test. Correlation of changes of sRAGE and HMGB1 was examined by a Pearson’s correlation. The differences of HMGB1 and sRAGE among groups (never smoker, current smokers and ex-smokers) of COPD were analyzed using Mann-Whitney U test. Multiple linear regression analysis were used to assess the relationship between HMGB1/sRAGE and COPD disease status, gender, age, course of disease, smoking history, FEV1% pred.

Results

Patient characteristics

Table 1 summarizes the demographic characteristics of all subjects. A total of 44 patients were evaluated (32 males, 12 females; age 68.2±8.5 years). A total of 30 patients were current or former smokers, they are mostly male, with a consumption of 39.5±17.6 pack-years. The hospitalization time of AECOPD was 14 (range, 12-17) days, and frequency of acute exacerbation in the 3 previous years was 0.53±0.21 times/year.

Table 1. The basic information of the study subjects.

Parameter	Value
N	44
Sex (male/female)	Dec-32
Age (years)	68.2±8.5
BMI (kg/m2)	24.4±4.2
Never/current/ex-smokers	14/19/11
Smoking history (pack-years)*	39.5±17.6
Hospitalization time [days]	14 [12-17]
Exacerbation frequency (times/year)	0.53±0.21
Course of disease (years)	10.3±5.4

BMI, body mass index; *, includes only 30 current/ex-smokers; Values are mean ± standard deviation (SD) or median (range).

Laboratory parameters

Total leucocytes counts, neutrophils %, arterial blood gas analysis, hsCRP, fibrinogen were determined and recorded at the time of admission and discharge. Pulmonary function was not performed at the time of admission due to worsening of physical status, and was examined before patients discharge. The laboratory parameters of subjects are shown in Table 2.

Table 2. Laboratory parameters of subjects.

Parameter	Acute exacerbation (range)	Convalescence (range)	P
White blood counts (109/L)	7.54±3.45	5.68±1.85	<0.01
Neutrophils % (%)	73.60±12.71	63.80±9.51	<0.01
PaO2 (mmHg)	66.40±8.65	76.42±9.78	<0.01
PaCO2 (mmHg)	42.26±8.20	41.4±4.11	0.346
FEV1% pred (%)	ND	47.5±13.5	ND
FEV1% FVC (%)	ND	46.2±12.2	ND
RV% TLC (%)	ND	48.0±9.3	ND
Serum hsCRP (mg/dL)	4.4 (0.57-21.4)	0.58 (0.3-3.54)	<0.01
Plasma fibrinogen (mg/dL)	358.18±109.97	258.32±60.22	<0.01
Plasma HMGB1 (ng/mL)	0.4668±0.0587	0.4215±0.0555	<0.01
Plasma sRAGE (ng/mL)	4.563±0.547	4.377±0.496	0.03

PaO₂, arterial oxygen pressure; PaCO₂, arterial carbon dioxide pressure; FEV1, forced expiratory volume at 1 s; % pred, percent of predicted value; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; hsCRP, high-sensitivity C-reactive protein; HMGB1, high-mobility group box1; sRAGE, soluble receptor for advanced glycation end products; ND, not done; Values are mean ± standard deviation (SD) or median (range).

Plasma HMGB1, sRAGE, fibrinogen and serum hsCRP levels in exacerbation and convalescence phase of COPD

The changes of plasma HMGB1, sRAGE, fibrinogen and serum hsCRP level are shown in Table 2 and Figure 1A-D. There was a significant decline in plasma HMGB1 (P<0.01), sRAGE (P<0.05), fibrinogen (P<0.01) and serum hsCRP (P<0.01) level from acute exacerbation to convalescence phase in COPD.

Figure 1.

Analysis of concentrations of plasma HMGB1 (A), sRAGE (B), fibrinogen (C), serum hsCRP (D) between acute exacerbation and convalescence of COPD (n=44). Values of HMGB1, sRAGE, fibrinogen are expressed as mean + SD and values of hsCRP are expressed as medians (interquartile range). HMGB1, high mobility group protein B1; sRAGE, soluble receptor for advanced glycation end products; hsCRP, high-sensitivity C-reactive protein; COPD, chronic obstructive pulmonary disease; *, P<0.05; ^#, P<0.01; SD, standard deviation.

Correlation of the changes of sRAGE and HMGB1 in exacerbation and convalescence phase

The correlation between the change of HMGB1 level and the change of sRAGE level in acute exacerbation and convalescence is shown in Figure 2. There was a significant positive correlation between the change of sRAGE and change of HMGB1 (r=0.4, P=0.007).

Figure 2.

The correlation between the change of HMGB1 and the change sRAGE from acute exacerbation to convalescence in chronic obstructive pulmonary (n=44, r²=0.16, P=0.007). HMGB1, high mobility group protein B1; sRAGE, soluble receptor for advanced glycation end products.

HMGB1/sRAGE ratio correlates with COPD disease status

In the multivariate linear regression analysis with HMGB1/sRAGE as a dependent variable, COPD disease status was found to be an only major influence factor affecting HMGB1/sRAGE ratio (unadjusted r²=0.102, adjusted r²=0.036), whereas gender, age, course of disease, smoking history and FEV1% pred did not appear to be significant factors influencing HMGB1/sRAGE ratio (Table 3).

Table 3. Multivariate linear regression of all subjects with HMGB1/sRAGE as the dependent variable.

Parameter	B*	β#	t	P
Constant	0.109		7.506	<0.01
Disease statue	–0.007	–0.267	–2.534	0.013
Sex (male/female)	–0.003	–0.113	–0.825	0.412
Age (years)	8.29	0.055	0.444	0.658
Course of disease (years)	6.29	0.056	0.425	0.672
Smoking statue	0.001	0.038	0.27	0.788
FEV1% pred (%)	5.31	–0.057	–0.495	0.622

FEV1, forced expiratory volume at 1 s; % pred, percent of predicted value; Definition of disease statue: acute exacerbation COPD =1, convalescence COPD =2; Sex: male =1, female =2; Smoking statue: never smokers =0, ex-smokers =1, current smokers =2; B*, non-standardised coefficient; β^#, standardised coefficient.

HMGB1 and sRAGE levels with smoking

Subjects with COPD were classified into three groups of never smoker, current smoker and ex-smoker according to smoking history. Table 4 shows that the level of HMGB1 was the highest in current smoker group, and decreased significantly in ex-smoker group in either acute exacerbation or convalescence phase. However, HMGB1 level was higher in never smoker group than ex-smoker group. The change of sRAGE level had a similar pattern.

Table 4. The effects of smoking on the levels of HMGB1 and sRAGE in COPD patients.

Parameter	Never smoker (range)	Ex-smokers (range)	Current smokers (range)	P1	P2	P3
Sex (male/female)	4/10	10/1	1/18	0.002	<0.01	0.685
Age (years)	71.57±7.94	66.63±7.34	66.52±9.08	0.125	0.107	0.973
FEV1% pred (%)	47.28±12.38	43.12±19.23	51.11±10.29	0.518	0.339	0.223
A-HMGB1 (ng/mL)	0.477 (0.376-0.572)	0.404 (0.376-0.522)	0.480 (0.355-0.600)	0.062	0.559	0.028
A-sRAGE (ng/mL)	4.699±0.351	4.193±0.673	4.563±0.512	0.021	0.985	0.043
C-HMGB1 (ng/mL)	0.422±0.047	0.385±0.058	0.443±0.056	0.106	0.177	0.012
C-sRAGE (ng/mL)	4.411 (3.583-5.256)	4.234 (2.652-4.742)	4.487 (3.782-5.360)	0.125	0.402	0.021

FEV1, forced expiratory volume at 1 s; % pred, percent of predicted value; A-HMGB1, high-mobility group box1 levels of acute exacerbation of COPD; C-HMGB1, high-mobility group box1 levels of convalescence of COPD; A-sRAGE, soluble receptor for advanced glycation end products of acute exacerbation of COPD; C-sRAGE, soluble receptor for advanced glycation end products of convalescence of COPD; P1, ex-smokers compared with never smoker; P2, current smokers compared with never smoker; P3, current smokers compared with ex-smokers.

Discussion

The episode of COPD exacerbation is characterized by an increase of various inflammatory markers in lung, including neutrophils, macrophages and various cytokines (12). The activation of NF-κB plays a critical role in inflammatory responses of COPD exacerbation (13). Studies have shown that extracellular HMGB1 is a critical mediator in late stage of inflammatory responses, HMGB1 signals through RAGE leading to activation of NF-κB and subsequent up-regulation of various leukocyte adhesion molecules, membrane receptor and pro-inflammatory cytokines, such as IL-1β, IL-6, TNF-α and RAGE (14,15). These pro-inflammatory cytokines in turn promote hepatic synthesis of hsCRP and fibrinogen (12). High level of RAGE is expressed in alveolar epithelial cells and alveolar macrophages and is thought to be important in the pathogenesis of COPD (4). Studies have shown that plasma HMGB1 level in COPD patients is significantly greater than that in healthy controls. We showed here that HMGB1 was also associated with the occurrence of AECOPD, its level raised in the AECOPD, and declined in convalescence phase of COPD. It seems that HMGB1 may be not only a potential inflammatory marker in COPD but also a therapeutic target for COPD.

sRAGE corresponds to the extracellular domain of membrane-bound RAGE lacking its cytosolic and transmembrane domains, and exists in extracellular fluids. sRAGE may act as a decoy receptor binding RAGE ligands and preventing them binding to membrane RAGE (5). Numerous studies have reported that a correlation between sRAGE level and inflammatory diseases, for example, sRAGE level was elevated in BAL fluid and plasma in patients with acute lung injury, it was positively correlated with the severity of acute lung injury (16). In our study, we also observed that the level of plasma sRAGE was higher in AECOPD than that of convalescence. These results seem inconsistent with the notion that sRAGE functions to decoy HMGB1. Study by Smith et al. suggested that sRAGE was lower in stable COPD than in healthy control, and AECOPD was associated with even lower sRAGE level, sRAGE increased with COPD convalescence (9). This discrepancy may be due to several reasons. In Smith’s study, the comorbidities of patients with AECOPD and oxygen therapy in these patients were not counted and analyzed. AECOPD is associated with worsening hypoxia and activation of NF-κB, which increases expression of membrane RAGE (17). Soluble RAGE is generated by proteolytic cleavage of membrane-bound RAGE (18), this process is mediated by disintegrin, metalloprotease (ADAM10) (19) and matrix metalloproteinase-9 (MMP-9) (20). It has also been shown that MMP-9 activity and ADAM10 expression are increased in AECOPD compared to convalescence of COPD (21-23), which stimulate membrane RAGE shedding and promote the release of sRAGE (20). In addition, HMGB1 has also been found to induce RAGE shedding (24).

The results of the present study suggested that gender, age, course of disease, smoking history and FEV1% pred did not significantly affect HMGB1/sRAGE ratio. COPD disease status was found to be an only major factor affecting HMGB1/sRAGE ratio. The ratio of HMGB1/sRAGE was elevated in exacerbation of COPD and declined in convalescence of COPD, suggesting that although both levels of HMGB1 and sRAGE were increased in AECOPD, the elevation of HMGB1 was predominant. Our study further indicated that the levels of HMGB1 and sRAGE in circulation were the highest in currently smoking COPD patients, and the lowest levels were in ex-smoker COPD patients. We inferred that smoking can induce the elevation of HMGB1 levels, which were declined by quitting smoking. Cigarette smoke was an extremely concentrated sources of ROS and reactive nitrogen species (25), which activates inflammasomes leading to releasing HMGB1 (26). As mentioned above, HMGB1 stimulate RAGE shedding and promote the release of sRAGE, the trend of sRAGE level had a similar with HMGB1. However, the reasons for levels of HMGB1 and sRAGE higher in never smoking COPD than ex-smoking COPD were still unclear.

Limitations of this study include small sample size, lack of measurement of lung function prior to treatment of AECOPD, and lack of complete long-term follow-up. Despite such limitations, this study provides valuable preliminary information about changes of HMGB1 and sRAGE in COPD exacerbation episodes.

Conclusions

The present study showed that the levels of plasma HMGB1, sRAGE, fibrinogen and hsCRP were elevated in AECOPD and tended to decline in convalescence of COPD; the ratio of HMGB1/sRAGE was correlated with status COPD. Meanwhile, the reduction of plasma HMGB1 was correlated with the reduction of plasma sRAGE from acute exacerbation phase to convalescence phase. The concentrations of plasma HMGB1 and sRAGE in patients with COPD were influenced by smoking.